Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-03-08
2005-03-08
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S533000, C514S568000, C560S017000, C560S061000, C560S062000, C560S081000, C562S471000, C562S472000, C562S488000, C558S414000
Reexamination Certificate
active
06864287
ABSTRACT:
The present invention relates to the compounds of the general formula (I)and their salts and stereoisomers for the production of medicaments for the treatment of cardiovascular disorders.
REFERENCES:
patent: 5041638 (1991-08-01), Rosentreter et al.
patent: 0341551 (1989-11-01), None
patent: 0410241 (1991-01-01), None
patent: 0296732 (1991-10-01), None
patent: 0494621 (1992-07-01), None
patent: 0791576 (1997-08-01), None
patent: 9816223 (1998-04-01), None
patent: 9816507 (1998-04-01), None
patent: 9823619 (1998-06-01), None
Ko, F., Wu, C., Kuo, S., Lee, F., Tend, C., “YC-1, A Novel Activator of Platelet Guanylate Cyclase”, Blood, 84: 4226-4233 (1994).
Mulsch, A., Bauersachs, J., Schafer, A., Stasch, J., Kast, R., Busse, R., “Effect of YC-1, An NO-Independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, On Smooth Muscle Responsiveness to Nitrovasodilators”, Br. J. Pharmacol., 120: 681-689 (1997).
Glass, D., Frey, W., Carr, D., Goldberg, N., “Stimulation of Human Platelet Guanylate Cyclase by Faty Acids”, J. Biol. Chem., 252: 1279-1285 (1977).
Pettibone, D., Sweet, C., Risley, E., Kennedy, T., “A Structurally Novel Stimulator of Guanylate Cyclase With Long-lasting Hypotensive Activity in the Dog”, Eur. J. Pharmacol., 116: 307-312 (1985).
Yu, S., Kuo, S., “Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, in Rat Aorta”, Br. J. Pharmacol., 114: 1587-1594 (1995).
Gerzer, R., Bohme, E., Hofmann, F., Schultz, G., “Soluble Guanylate Cyclase Purified From Bovine Lung Contains Heme And Copper”, FEBS Lett., 132: 71-74 (1981).
Hoenicka, M., Becker, E., Apeler, H., Sirichoke, T., Schroder, H., Gerzer, R., Stasch, P., “Purified Soluble Guanylyl Cyclase Expressed in a Baculovirus/Sf9 System: Stimulation by YC-1, Nitric Oxide, and Carbon Monoxide”, J. Mol. Med., 77: 14-23 (1999).
Ignarro, L., “Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins”, Adv. Pharmacol., 26: 35-65 (1994).
Mulsch, A., Bauersachs, J., Stasch, J., Busse, R., “Potentiation of Vascular Responses To No-Donors By an No-Independent Activator of Soluble Guanylyl Cyclase”, Naunyn Schmiedebergs Arch. Pharmacol., 355: R47.
Alonso-Alija Cristina
Dembowsky Klaus
Flubacher Dietmar
Heil Markus
Naab Paul
Bayer Aktiengesellschaft
Powers Fiona T.
LandOfFree
Derivatives of dicarboxylic acid having pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of dicarboxylic acid having pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of dicarboxylic acid having pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446608